Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab


Tonyali O., Coskun U., Yuksel S., İNANÇ M., Bal O., Akman T., ...More

BREAST, vol.25, pp.22-26, 2016 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25
  • Publication Date: 2016
  • Doi Number: 10.1016/j.breast.2015.11.006
  • Journal Name: BREAST
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.22-26
  • Keywords: Breast cancer, Adjuvant therapy, Trastuzumab, Brain metastasis, CENTRAL-NERVOUS-SYSTEM, RANDOMIZED-TRIALS, RECEPTOR STATUS, SURVIVAL, METAANALYSIS, CHEMOTHERAPY, SUBTYPES, THERAPY, NETWORK

Abstract

Purpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab.